Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Status:
Not yet recruiting
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the impact of taking drugs (agents) that target altered brain
metabolism following standard of care brain radiotherapy. Radiotherapy uses high energy
x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. However,
radiotherapy can also cause harmful effects to normal brain functioning. One drug, called
anhydrous enol-oxaloacetate (AEO), has previously been studied in ischemic stroke,
Alzheimer's disease, Parkinson's disease, and glioma. Drugs such as AEO may help preserve or
restore healthy brain function after brain radiotherapy compared to the standard practice
which consists of no drugs.